Get started
Author

Martin Kornacker

Observed names: Kornacker Martin, Kornacker, Martin, Kornacker, Martin 1966-, M Kornacker, M. Kornacker
Institution: Roche (Switzerland)
Observed institutions: Roche (Switzerland), University of Cologne, Heidelberg University, University Medical Center Freiburg, University Hospital Heidelberg, Bayer (Switzerland), Janssen (Germany), Stanford Medicine, Bayer (Germany), Stanford University
ORCID: 0000-0002-3502-928X
Observed ORCID: 0000-0002-3502-928X
OpenAlex ID: A5065202186
Comparison of Immunological Properties of Bone Marrow Stromal Cells and Adipose Tissue–Derived Stem Cells Before and After Osteogenic Differentiation In Vitro
2007 · Philipp Niemeyer, Martin Kornacker, et al. · Tissue Engineering · 179
Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells
1996 · J Wolf, U Kapp, et al. · Blood · 178
PDF
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
2019 · Andrew D. Zelenetz, Gilles Salles, et al. · Blood · 136
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
2020 · Geoffrey I. Shapiro, Patricia LoRusso, et al. · British Journal of Cancer · 115
PDF
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
2013 · B. Schultheis, G. Folprecht, et al. · Annals of Oncology · 95
PDF
Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia
2003 · Manfred Hensel, Martin Kornacker, et al. · British Journal of Haematology · 66
PDF
Resistance of ex vivo expanded CD3 + CD56 + T cells to Fas-mediated apoptosis
2000 · Michael R. Verneris, Martin Kornacker, et al. · Cancer Immunology Immunotherapy · 66
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
2020 · Pier Luigi Zinzani, Ian W Flinn, et al. · PubMed · 65
Cytokine‐induced killer cells against autologous CLL: Direct cytotoxic effects and induction of immune accessory molecules by interferon‐γ
2006 · Martin Kornacker, Gerhard Moldenhauer, et al. · International Journal of Cancer · 65
PDF
Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up
2009 · M. Kornacker, J. Stumm, et al. · Annals of Oncology · 61
PDF
Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells
2001 · Martin Kornacker, Michael R. Verneris, et al. · Immunology Letters · 60
Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases
2002 · M. Kornacker, A. Kraemer, et al. · Annals of Hematology · 56
Pentostatin/Cyclophosphamide with or Without Rituximab: An Effective Regimen for Patients with Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma
2005 · Manfred Hensel, Matthias Villalobos, et al. · Clinical Lymphoma & Myeloma · 49
Somatic Mutations Within the Untranslated Regions of Rearranged Ig Genes in a Case of Classical Hodgkin’s Disease as a Potential Cause for the Absence of Ig in the Lymphoma Cells
1999 · Andrea Jox, Thomas Zander, et al. · Blood · 46
Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
2002 · Christian Scheffold, Martin Kornacker, et al. · PubMed · 45
Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib
2022 · Ulrike Obst-Sander, Antonio Ricci, et al. · Journal of Medicinal Chemistry · 44
Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells
2007 · Freddy Tita-Nwa, Gerhard Moldenhauer, et al. · Cancer Immunology Immunotherapy · 37
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
2021 · Michael Dickinson, Javier Briones, et al. · Blood Advances · 35
PDF
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome
2021 · Gail J. Roboz, Pinkal Desai, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 35
Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study
2018 · Franck Morschhauser, Pierre Feugier, et al. · Blood · 33
Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells
2005 · Michael R. Verneris, Arash Arshi, et al. · Clinical Cancer Research · 33
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies
2017 · Rastislav Bahleda, Juneko E Grilley-Olson, et al. · British Journal of Cancer · 30
PDF
Hodgkin disease‐derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis
2001 · Martin Kornacker, Uwe Schlattner, et al. · International Journal of Cancer · 25
PDF
Combined effect of recombinant CD19xCD16 diabody and thalidomide in a preclinical model of human B cell lymphoma
2004 · Jana Schlenzka, Thomas M. Moehler, et al. · Anti-Cancer Drugs · 23
Detection of identical Hodgkin–Reed Sternberg cell specific immunoglobulin gene rearrangements in a patient with Hodgkin’s disease of mixed cellularity subtype at primary diagnosis and in relapse two and a half years later
1998 · A. Jox, T. Zander, et al. · Annals of Oncology · 23
PDF
Works count: 109
Citation count: 1,923
H-index: 23
I10-index: 37
Year
Topic
Type